Endovastec's 2026 interim report shows net profit of 322 million yuan

Jiemian··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Endovastec released its 2026 interim report, with total operating revenue of 794 million yuan and net profit attributable to the parent company of 322 million yuan. Net cash inflow from operating activities was 290 million yuan, down 9.11% from the same period last year. The company's asset-liability ratio was 13.72%, gross margin was 71.36%, ROE was 7.57%, and diluted earnings per share was 2.67 yuan. The number of shareholders was 16,200, and the top ten shareholders held 46.51% of the total share capital.

Impact on assets 1

Others▲ · 1 stocks
© 2026 MarketIVNews